Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

NCT03489525 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03489525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03489525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
May 8, 2018
Completion date
March 21, 2022
Enrollment
107 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma